PRESS RELEASE published on 01/05/2024 at 22:15, 8 months 23 days ago Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Jaguar Health, Inc. (NASDAQ:JAGX) granted 7,500 restricted stock units (RSUs) to a new employee, with vesting over three years. The RSUs were approved by the Compensation Committee of Jaguar's Board and are subject to the employee's continued service. Jaguar Health is a pharmaceutical company focused on developing prescription medicines derived from plants for gastrointestinal distress. Jaguar Health Inc NASDAQ JAGX Restricted Stock Units Pharmaceuticals Gastrointestinal Distress
PRESS RELEASE published on 01/04/2024 at 14:30, 8 months 24 days ago Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) Napo Pharmaceuticals, a Jaguar Health family company, has received a new U.S. patent for methods to treat congenital diarrheal disorders with crofelemer, their novel plant-based prescription drug. This patent enhances their intellectual property protection for crofelemer and supports their focus on rare disease indications such as microvillus inclusion disease and short bowel syndrome. Jaguar is conducting investigator-initiated studies for these rare disease indications in multiple regions with results expected in 2024. Napo Pharmaceuticals Crofelemer Rare Disease Indications Microvillus Inclusion Disease Short Bowel Syndrome
PRESS RELEASE published on 12/11/2023 at 14:30, 9 months 17 days ago A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
PRESS RELEASE published on 12/07/2023 at 14:30, 9 months 21 days ago MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
PRESS RELEASE published on 12/06/2023 at 14:30, 9 months 22 days ago Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website Napo Pharmaceuticals and Advocates for Collaborative Education (ACE) have released the abstract for a quality of life survey for individuals with a cancer diagnosis, shedding light on the challenges faced. The survey findings will be presented at the December 2023 SABCS, focusing on the impacts of cancer diagnosis and treatment on quality of life, including physical and emotional well-being, treatment side effects, and the consequences of managing those side effects Napo Pharmaceuticals Advocates For Collaborative Education Cancer Survey Quality Of Life SABCS 2023
PRESS RELEASE published on 12/04/2023 at 14:30, 9 months 24 days ago FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs Jaguar Health, Inc. (NASDAQ:JAGX) has announced the renewal of conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) by the U.S. FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The renewal extends the validity until December 21, 2024, as the company plans a clinical field study to support full approval Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
PRESS RELEASE published on 11/30/2023 at 14:30, 9 months 28 days ago Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference Jaguar Health, Inc. to present on Dec 5, 2023, at the MedInvest Oncology Investor Conference, discussing pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy Crofelemer Jaguar Health Oncology Investor Conference Phase 3 Clinical Trial Cancer Therapy
PRESS RELEASE published on 11/21/2023 at 14:30, 10 months 7 days ago Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
PRESS RELEASE published on 11/14/2023 at 14:00, 10 months 14 days ago Jaguar Health Reports Third Quarter 2023 Financial Results
PRESS RELEASE published on 11/10/2023 at 22:15, 10 months 18 days ago Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published on 09/28/2024 at 02:06, 1 day 3 hours ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 1 day 3 hours ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 5 hours ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 15 hours 31 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 7 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 7 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 10 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 10 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 11 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 11 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 11 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 11 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024